Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00583817 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Endovascular Treatment of Thoracic Aortic Disease

Study acronym: EVOLVE Aorta
StatusEnrolling by Invitation
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 2027 to Dec 2030
    • Study sites: 1 to 2
    • Eligibility criteria expanded, about 26 words
    v26
  2. Eligibility criteria expanded, about 15 wordsv25
  3. 3 versions Re-verified since Mar 6, 2019, no change to tracked fieldsv22-v24
  4. Primary and study completion dates: Dec 2020 to Dec 2027v21 Show 4 more changesShow less
    • Start date: May 2001 to Oct 25, 2018
    • Primary endpoints: 1 to 3
    • Eligibility criteria expanded, about 1,305 words
    • Study description expanded, about 359 words
  5. Enrollment target: 35 to 170v20 Show 8 more changesShow less
    • Primary endpoint revised
    • Trial status: Recruiting to Enrolling by Invitation
    • Eligibility criteria expanded, about 49 words
    • Study description shortened, about 11 words
    • Study site revised
    • Collaborator revised
    • Study arms: 2 to 3
    • Study title shortened, about 2 words
Show 18 earlier versionsHide 18 earlier versions
  1. Re-verified, no change to tracked fieldsv19
  2. Phase: Phase 1 to Not applicablev18 Show 6 more changesShow less
    • Enrollment target: 459 to 35
    • Eligibility criteria expanded, about 42 words
    • Study description shortened, about 40 words
    • Site contact updated
    • Study arms: 1 to 2
    • Study title expanded, about 2 words
  3. Primary endpoint revised
    • Study description expanded, about 216 words
    • Site contact updated
    • Study arms: 4 to 1
    v17
  4. Lead sponsor: The Cleveland Clinic to Matthew Eagleton
    • Collaborator revised
    v16
  5. 2 versions Re-verified since Nov 8, 2014, no change to tracked fieldsv14-v15
  6. Site contact updatedv13
  7. Site contact updated
    • Collaborator revised
    v12
  8. Site contact updatedv11
  9. 2 versions Re-verified since Nov 5, 2012, no change to tracked fieldsv9-v10
  10. Interventions: Endovascular stent graft (Procedure) to Endovascular stent-graft implantation (Device)v8
  11. Enrollment target: 449 to 459v7
  12. Re-verified, no change to tracked fieldsv6
  13. Enrollment target: 439 to 449
    • Study arms: 3 to 4
    v5
  14. Enrollment target: 412 to 439v4
  15. Primary endpoint revised
    • Interventions: Endovascular stentgraft (Procedure) to Endovascular stent graft (Procedure)
    v3
  16. Site contact updatedv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the role endovascular therapy to treat aortic disease involving the ascending aorta, the aortic arch, and the visceral segment of the aorta (or thoracoabdominal aorta)
Trial Details
NCT Number NCT00583817
Lead Sponsor Matthew Eagleton
Collaborators: Massachusetts General Hospital
Conditions
(from sponsor)		 Thoracic Aortic Aneurysms, Dissecting, Aneurysm, Ascending Aorta Aneurysm, Aortic Arch; Aneurysm, Dissecting, Ascending Aortic Dissection, Thoracoabdominal Aortic Aneurysm, Renal Artery Aneurysm, Superior Mesenteric Artery Aneurysm +1 more
Related terms Aneurysm, Aneurysm, Ascending Aorta, Aortic Aneurysm, Thoracic, Aortic Aneurysm, Thoracoabdominal, Aortic Dissection, Dissection, Ascending Aorta
Enrollment 170 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov